Optimizing Choices and Sequences in the Diagnostic-Therapeutic Landscape of Advanced Triple-Negative Breast Cancer: An Italian Consensus Paper and Critical Review

A panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers addressed 26 high-priority statements, including grey areas, regarding the management of triple-negative metastatic breast cancer. The Panel produced a set of prioritized considerations/consensus statements reflecting the Panel position on diagnostic and staging approach, first-line and second-line treatments of PD-L1-positive/germline BRCA (gBRCA) wild-type, PD-L1-positive/gBRCA mutated, PD-L1-negative/gBRCA wild-type, and PD-L1-negative/gBRCA mutated triple-negative metastatic breast cancer.